A new weight loss pill outperformed Novo Nordisk's version
Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill.
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Novo Nordisk A/S (NYSE:NVO) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...
Seeking Alpha6d
Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Transcript
Novo Nordisk remains the market leader in international ... been initiated with once-weekly subcutaneous and once-daily oral amycretin in people with type 2 diabetes in Q3. And we're anticipating ...
Viking Therapeutics Offers An Obesity Drug for Healthy Adults
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...
Investing19d
Novo Nordisk's SWOT analysis: supply constraints challenge strong obesity drug growth
Similarly, successful trials for CagriSema or oral amycretin could provide Novo Nordisk with next-generation products to drive growth beyond its current portfolio. Positive data could also support ...